Covalent Tolerance Induction to Factor VIII-Prediction of Inhibitors in Hemophilia
Summary
To correlate the HLA type and genetic defect with hemophilia A.
Description
One of the most serious complications of treatment in patients with hemophilia A or hemophilia B is the development of an inhibitor, which is an antibody that neutralizes the factor VIII or IX coagulant activity. Up to one fourth of patients with severe hemophilia A develop an inhibitor but at present it is not possible to predict which patients will develop such antibody. The ability to predict an inhibitor development at an individual level would greatly improve therapeutic approach to this serious problem
Study Design
Observational Model: Case-Only, Time Perspective: Prospective
Conditions
Hemophilia A
Location
The Univeristy of Texas Health Science Center at Houston
Houston
Texas
United States
77030
Status
Recruiting
Source
The University of Texas Health Science Center, Houston
Results (where available)
Links
- Source: http://clinicaltrials.gov/show/NCT00178607
- Information obtained from ClinicalTrials.gov on July 15, 2010
Medical and Biotech [MESH] Definitions
Hemophilia B
A deficiency of blood coagulation factor IX inherited as an X-linked disorder. (Also known as Christmas Disease, after the first patient studied in detail, not the holy day.) Historical and clinical features resemble those in classic hemophilia (HEMOPHILIA A), but patients present with fewer symptoms. Severity of bleeding is usually similar in members of a single family. Many patients are asymptomatic until the hemostatic system is stressed by surgery or trauma. Treatment is similar to that for hemophilia A. (From Cecil Textbook of Medicine, 19th ed, p1008)
Hemophilia A
The classic hemophilia resulting from a deficiency of factor VIII. It is an inherited disorder of blood coagulation characterized by a permanent tendency to hemorrhage.
Factor Xi Deficiency
A hereditary deficiency of blood coagulation factor XI (also known as plasma thromboplastin antecedent or PTA or antihemophilic factor C) resulting in a systemic blood-clotting defect called hemophilia C or Rosenthal's syndrome, that may resemble classical hemophilia.
Hemarthrosis
Bleeding into the joints. It may arise from trauma or spontaneously in patients with hemophilia.
Factor Xi
Stable blood coagulation factor involved in the intrinsic pathway. The activated form XIa activates factor IX to IXa. Deficiency of factor XI is often called hemophilia C.
Clinical Trials
Study Evaluating ReFacto in Hemophilia A
To identify the causative mutations in previously untreated patients with hemophilia A enrolled in the ReFacto® clinical safety and efficacy study CTN 93-R833-0XX/C9741-28, using two esta...
Females With Severe or Moderate Hemophilia A or B: A Multi-Center Study
To collect and analyze data on females with hemophilia so as to better define the difference between the study population and the male population with hemophilia.
Epidemiology and Immunology of Hemophilia A Inhibitors
To determine the risk factors associated with inhibitor formation in hemophilia A and to study the mechanism of tolerance in the murine hemophilia A model.
Bleeding Symptoms of Carriers of Hemophilia A and B
To collect and analyze data on female carriers of severe and moderate hemophilia A and B.
Study Evaluating BENEFIX in Previously Treated Patients With Hemophilia B
To assess efficacy and safety of BeneFix® for prophylaxis in "Short-term" therapy and on demand therapy for all bleeding episodes of subjects with hemophilia B.
PubMed Articles
Pseudotumor of hemophilia (PTH) is a rare complication seen in approximately 1-2% of cases of hemophilia. Although much more common in long bones, the pelvis, and small bones of the hands and feet tha...
Assessment of blood-induced arthritis causes friction.
Is a reduced intensity treatment with Rituximab effective in acquired haemophilia A?
Recent studies report reduced bone mineral density (BMD) even among young adults and children with hemophilia. Our aim was to assess bone status in children and adolescents with hemophilia with 2 meth...
Another role for the VW molecule.
Summary. My comments on the implication of the vW molecule in down-regulating the immunogenicity of factor VIII.
